Recent pan cancer analyses using The Cancer Genome Atlas (TCGA) across 23 cancer types, followed by tissue microarray (TMA) expression validation, revealed high CDK19 expression in primary prostate tumors and high expression of both, CDK8 and CDK19 in prostate cancer metastases (Brägelmann et al., 2017). This evidence concerns the gene CDK19 and prostate neoplasm.